SIGLEC9 and breast carcinoma: Analysis of the immune cells expressing Siglec‐7 and Siglec‐9 in the breast cancer TME revealed Siglec‐7 expression on CD3+ T cells, CD11b+ myeloid cells and CD56+ NK cells, and Siglec‐9 on CD11b+ cells.